What is the recommended dosing regimen and safety considerations for initiating bupropion XL (bupropion extended‑release) to a target dose of 300 mg daily?

Bupropion XL 300 mg: Dosing Regimen and Safety Considerations

Start bupropion XL at 150 mg once daily in the morning, then increase to the target dose of 300 mg once daily after 4 days for major depressive disorder. 1

Standard Initiation Protocol

• Begin with 150 mg orally once daily in the morning for the first 4 days of treatment. 1
• After 4 days, increase to 300 mg once daily in the morning if the medication is tolerated. 1
• Administer the dose in the morning to minimize insomnia risk; bupropion XL's extended-release design is optimized for once-daily morning dosing. 2, 1
• Swallow tablets whole—do not crush, divide, or chew, as this disrupts the extended-release mechanism. 1
• May be taken with or without food. 1

Critical Safety Monitoring in the First 1–2 Weeks

Intensive monitoring for neuropsychiatric adverse effects must begin within the first 1–2 weeks, as this period carries the highest risk for serious events. 2, 1

Specific symptoms to assess:

• Suicidal ideation or behavior 2, 1
• Agitation, irritability, or hostility 2
• Unusual behavioral changes or impulsivity 2
• Worsening depression or anxiety 2
• New-onset panic symptoms 2

Continue close monitoring for at least the first 2 months of therapy, as neuropsychiatric risk remains elevated during this period. 2

Timeline for Therapeutic Response

• Early activation or energy improvement may appear within days to weeks of starting treatment. 2
• A full therapeutic trial requires 4–8 weeks at an adequate dose before determining efficacy. 3, 2
• Reassess treatment adequacy at 6–8 weeks; if response is insufficient, consider dose adjustment, augmentation, or switching agents. 2

Absolute Contraindications

Do not prescribe bupropion XL in patients with:

• Seizure disorders or any condition lowering seizure threshold (e.g., eating disorders, stroke, brain metastases, abrupt alcohol/benzodiazepine discontinuation)—this is an absolute contraindication. 2, 1
• Current or recent (within 14 days) MAOI use, due to hypertensive crisis risk. 1
• Closed-angle glaucoma. 2

Dose Adjustments for Organ Impairment

• Moderate-to-severe hepatic impairment (Child-Pugh 7–15): Maximum dose is 150 mg every other day. 1
• Mild hepatic impairment (Child-Pugh 5–6): Consider reducing dose and/or frequency. 1
• Renal impairment (GFR <90 mL/min): Consider reducing dose and/or frequency; in moderate-to-severe renal impairment, reduce total daily dose by 50%. 2, 1

Important Drug Interactions

• Tamoxifen: Bupropion is contraindicated because it inhibits CYP2D6, reducing tamoxifen's efficacy. 2
• Other CYP2D6 inhibitors may increase bupropion plasma levels. 2
• Reversible MAOIs (linezolid, IV methylene blue): Do not initiate bupropion in patients receiving these agents; if urgent treatment with these MAOIs is needed in a patient on bupropion, stop bupropion promptly and monitor for 2 weeks or 24 hours after the last MAOI dose, whichever comes first. 1

Clinical Situations Favoring Bupropion XL

• Patients with prominent fatigue, low energy, or apathy benefit from bupropion's activating dopaminergic and noradrenergic effects. 2, 4
• Individuals concerned about sexual dysfunction should prefer bupropion, which has significantly lower rates (≈8%) compared to SSRIs (18–30%). 2
• Comorbid smoking and depression: Bupropion addresses both conditions simultaneously. 2
• Hypersomnia or excessive daytime sleepiness may improve with bupropion's activating properties. 2

Clinical Situations to Avoid Bupropion XL

• Agitated depression: Bupropion's activating properties may worsen agitation. 3, 2
• Any seizure history or risk factors (absolute contraindication). 2, 1
• Patients requiring opioid therapy if considering the naltrexone/bupropion combination. 2

Common Adverse Effects

• Most frequent side effects include loss of appetite, insomnia, anxiety, agitation, dry mouth, headache, nausea, constipation, and tremor. 2
• Insomnia risk is minimized by strict morning administration; late-day dosing significantly increases sleep disturbance. 2

Maintenance Therapy Duration

• After remission of a first depressive episode, continue bupropion for 4–9 months to reduce relapse risk. 2
• For recurrent depression, longer maintenance therapy is recommended. 2
• When discontinuing 300 mg daily, taper to 150 mg once daily before stopping to limit withdrawal symptoms. 1

Pitfalls to Avoid

• Do not judge bupropion ineffective before completing a full 6–8 week trial at therapeutic dose—premature discontinuation may miss eventual benefit. 2
• Never administer late in the day, as this violates the pharmacokinetic design and increases insomnia risk. 2
• Do not use in patients with uncontrolled hypertension. 2
• Gradual dose escalation is mandatory to minimize seizure risk; never start at 300 mg. 1